novell is a leading provider of infrastructure software. our vision is helping people and technology to work as one. our mission is to help customers reduce the cost, complexity and risk of computing on any platform.
Keywords to Search:
novell worldwide
Company Address:
404 Wyman St # 500,WALTHAM,MA,USA
ZIP Code: Postal Code:
02451-1212
Telephone Number:
2032251800 (+1-203-225-1800)
Fax Number:
7814648000 (+1-781-464-8000)
Website:
www. novell. com
Email:
USA SIC Code(Standard Industrial Classification Code):
copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
How I treat ALK-positive non-small cell lung cancer - PMC Since the discovery of anaplastic lymphocyte kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) and subsequent development of increasingly effective and central nervous system (CNS)-penetrant first-generation, second-generation and
Lorlatinib Versus Crizotinib in Patients With Advanced ALK . . . Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK -positive non–small cell lung cancer (NSCLC) in the phase III CROWN study Here, we report long-term outcomes from CROWN after 5 years of follow-up
Treatment Options for ALK+ - ALK Positive Treatment Options While our tumors share the ALK fusion gene, no two are identical There are many other differences in the tumor that may need to be considered in therapy planning Once you’re diagnosed with ALK+ lung cancer, your oncologist will determine the stage of your lung cancer and consider other factors for personalizing your treatment
Real-world treatment sequencing and effectiveness of second . . . With multiple targeted therapies approved for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), it is increasingly important to understand outcomes with various sequences of next-generation ALK tyrosine kinase inhibitors (TKIs) We describe contemporary sequencing patterns and treatment effectiveness of first-line (1L) and second-line (2L) treatments in
ALK and Lung Cancer - American Lung Association ALK stands for anaplastic lymphoma kinase It was originally described in lymphoma, but most ALK-positive cancers are in non-small cell lung cancer
Anaplastic lymphoma kinase (ALK)-positive advanced non-small . . . INTRODUCTION Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that can be aberrantly expressed in several tumor types In non-small cell lung cancer (NSCLC), chromosomal rearrangements involving the ALK gene loci on chromosome 2 are found in approximately 3 to 5 percent of NSCLC tumors [1,2] The most common ALK rearrangement in NSCLC juxtaposes the 5' end of the echinoderm microtubule
Evaluating Diagnostic and Treatment Timelines for ALK . . . Anaplastic Lymphoma Kinase (ALK)-positive nonsmall cell lung cancer (NSCLC) primarily affects younger, nonsmoking individuals Tyrosine kinase inhibitors (TKIs) have improved survival While timely diagnosis and TKI initiation are critical, global data on diagnostic and treatment timelines remain scarce This study examines key intervals from the first medical visit to diagnosis and treatment